01 / DESIGN
What was studied?
A nephrology clinic followed sixty-two adults with chronic kidney disease, diabetes and obesity after tirzepatide was prescribed in routine care.
02 / FINDINGS
What did the researchers report?
The cohort showed changes in weight, glycemic markers and albuminuria without an observed worsening of kidney function over the reported follow-up.
03 / LIMITS
How should it be interpreted?
There was no randomized comparator. Concurrent care, selection and incomplete follow-up can influence results; the study cannot establish a causal kidney-protection effect.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.